End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.5 USD | +1.97% | +7.09% | +26.31% |
Apr. 30 | Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals | MT |
Apr. 30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
Financials (USD)
Sales 2024 * | 321M | Sales 2025 * | 606M | Capitalization | 4.05B |
---|---|---|---|---|---|
Net income 2024 * | -149M | Net income 2025 * | 30M | EV / Sales 2024 * | 17.2 x |
Net Debt 2024 * | 1.46B | Net Debt 2025 * | 1.28B | EV / Sales 2025 * | 8.78 x |
P/E ratio 2024 * |
-24.3
x | P/E ratio 2025 * |
140
x | Employees | 999 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.24% |
Latest transcript on Alvotech
1 day | +1.97% | ||
1 week | +7.09% | ||
1 month | +16.28% | ||
3 months | -9.09% | ||
6 months | +68.80% | ||
Current year | +26.31% |
Managers | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 18-11-01 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 20-01-31 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 68 | 22-06-15 |
Helga Zharov
LAW | General Counsel | 57 | 20-04-30 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 18-11-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 14.48 | -0.14% | 118,095 |
24-04-30 | 14.5 | +1.97% | 224,692 |
24-04-29 | 14.22 | +0.49% | 39,632 |
24-04-26 | 14.15 | +3.66% | 248,476 |
24-04-25 | 13.65 | +0.81% | 65,564 |
End-of-day quote Nasdaq, April 29, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.31% | 4.05B | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- ALVO Stock